Serelaxin

Generic Name: Serelaxin

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 99489-94-8

Unique Ingredient Identifier: W0122B976Y

Background: Recombinant human relaxin is a hormone produced during pregnancy that facilitates the birth process by causing a softening and lengthening of the cervix and the pubic symphysis (the place where the pubic bones come together).It is a heterodimer protein secreted by the corpus luteum and placenta during pregnancy.

Indication: Investigated for use/treatment in cardiovascular disorders, congestive heart failure, infertility, peripheral vascular disease, and scleroderma.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Serelaxin To Lower Portal Pressure

Phase 2

Completed

Conditions: Liver Cirrhosis
Hypertension, Portal

Interventions: Drug: Placebo
Drug: Serelaxin

First Posted Date: 2016-02-01

Last Posted Date: 2018-10-11

Lead Sponsor: University of Edinburgh

Target Recruit Count: 15

Registration Number: NCT02669875

Locations: 🇬🇧
Liver Unit, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom

Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure

Phase 2

Terminated

Conditions: Chronic Heart Failure

Interventions: Drug: Serelaxin
Drug: Placebo

First Posted Date: 2015-12-09

Last Posted Date: 2018-09-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 26

Registration Number: NCT02625922

Locations: 🇬🇧
Novartis Investigative Site, Tyne And Wear, United Kingdom

Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure

Phase 2

Terminated

Conditions: Acute Heart Failure

Interventions: Drug: Serelaxin

First Posted Date: 2014-05-30

Last Posted Date: 2019-06-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 12

Registration Number: NCT02151383

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients

Phase 3

Terminated

Conditions: Acute Heart Failure (AHF)

Interventions: Drug: Serelaxin
Drug: Standard of Care

First Posted Date: 2014-02-17

Last Posted Date: 2019-03-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2666

Registration Number: NCT02064868

Locations: 🇬🇧
Novartis Investigative Site, Swindon, United Kingdom

Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF

Phase 3

Terminated

Conditions: Acute Heart Failure

Interventions: Drug: Placebo
Drug: Serelaxin
Other: Standard of CareTherapy

First Posted Date: 2013-12-11

Last Posted Date: 2019-08-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 876

Registration Number: NCT02007720

Locations: 🇹🇭
Novartis Investigative Site, Muang, Thailand

Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) Patients

Phase 2

Completed

Conditions: Acute Heart Failure

Interventions: Drug: Placebo
Drug: Serelaxin

First Posted Date: 2013-12-06

Last Posted Date: 2015-10-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 46

Registration Number: NCT02002702

Locations: 🇯🇵
Novartis Investigative Site, Itabashi-ku, Tokyo, Japan

Study of the Vascular Effects of Serelaxin

Phase 2

Completed

Conditions: Coronary Artery Disease

Interventions: Other: Placebo
Drug: Serelaxin

First Posted Date: 2013-11-08

Last Posted Date: 2019-07-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 58

Registration Number: NCT01979614

Locations: 🇬🇧
Novartis Investigative Site, Leicester, United Kingdom

PK of Serelaxin in Severe Renal Impairment and ESRD

Phase 1

Completed

Conditions: End-Stage Renal Disease
Renal Failure, Chronic

Interventions: Drug: Serelaxin

First Posted Date: 2013-06-12

Last Posted Date: 2020-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT01875523

Locations: 🇩🇪
Novartis Investigative Site, Grunstadt, Germany

Evaluation of the Safety of Relaxin in Preeclampsia

Phase 1

Suspended

Conditions: Pre-Eclampsia

First Posted Date: 2006-06-05

Last Posted Date: 2010-03-16

Lead Sponsor: Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies

Target Recruit Count: 18

Registration Number: NCT00333307

Locations: 🇺🇸
Central Baptist Hospital, Lexington, Kentucky, United States
🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States

Recombinant Human Relaxin (rhRlx) in Pregnant Women Scheduled for Induction of Labor

Phase 2

Completed

Conditions: Labor, Induced

Interventions: Drug: Placebo
Drug: Serelaxin

First Posted Date: 2005-11-29

Last Posted Date: 2014-05-07

Lead Sponsor: Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies

Target Recruit Count: 72

Registration Number: NCT00259103

Locations: 🇷🇺
D.O. Ott Research Institute of Obstetrics and Gynecology, Saint Petersburg, Russian Federation
🇷🇺
Novosibirsk State Medical Academy, Novosibirsk, Russian Federation
🇷🇺
Evidence CPR, Saint Petersburg, Russian Federation

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy